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Abstract
Transplantation provides a valuable, often life-saving, treatment for end-stage failure of many organs, including the heart, kidneys, liver, 
pancreas and lungs. It is also an important therapeutic option in diseases of the bone marrow and the immune system. Despite the un-
doubted benefits for transplant patients, it is associated with an increased risk of many complications. The potential causes include: poor 
general health of the patient, heavy burden of the surgery itself and the need for the long-term use of immunosuppression. In addition, 
the patients are also on numerous other medications, e.g. anti-coagulants, diuretics. Osteoporosis and high risk of fractures have emerged 
as frequent and devastating complications of the transplantation process. This article provides a review of the current literature on osteo-
porosis after transplantation, and the treatment options for this serious illness. (Pol J Endocrinol 2011; 62 (5): 472–485)
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Streszczenie
Transplantacja stanowi cenną i często jedyną metodę leczenia schyłkowej fazy niewydolności wielu narządów, między innymi serca, nerek, 
wątroby, trzustki oraz płuc. Z powodzeniem stosuje się ją również w chorobach układu odpornościowego i szpiku. Pomimo niewątpliwych 
korzyści dla chorego transplantacja wiąże się ze zwiększonym ryzykiem wielu powikłań z uwagi na duże obciążenie samym zabiegiem, 
często ciężki stan ogólny chorego oraz konieczność długotrwałego stosowania immunosupresji. Jednym z powikłań po przeszczepie 
może być również osteoporoza oraz związane z nią wysokie ryzyko złamań. Powyższa praca stanowi aktualny przegląd piśmiennictwa 
dotyczącego osteoporozy po przeszczepach oraz możliwości leczenia tej groźnej choroby. (Endokrynol Pol 2011; 62 (5): 472–485)
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Introduction
In 1988, there were 12,619 organs transplanted in the 
USA. That number increased to 25,468 by 2003 and, 
with the use of spouse donors, this will likely increase 
further [1].
The recognition and identification of the role of 
T lymphocytes and subsets, as well as of B lymphocytes 
in mediating immune reaction, involved in virtually 
every disease process, including, among others, infec-
tion, cancer, cardiovascular disease and organ trans-
plantation, have allowed the development of a class 
of drugs known as immune modulators [2, 3]. These 
drugs either enhance or suppress immune reaction, 
depending upon what type of modulation is required 
to affect disease outcome. 
In organ transplantation, the main requirement is 
to prevent or inhibit donor-organ rejection by the reci-
pient’s immune system. These immune-modulating 
drugs have an enormous impact on prolonging the 
lifespan of patients. This impact has not, however, been 
possible without certain costs, one of them being the 
effect of some of these agents on bone status. 
This review will focus on the effects of drugs, other 
than glucocorticoids, on bone. These drugs include 
calcineurin inhibitors (CIs), cyclosporine and tacrolimus 
and non-CIs: rapamycin, mycophenolate mofetil, meth-
otrexate, and azathioprine. A number of other immu-
nosuppressive drugs are at the disposal of physicians, 
and the list is steadily growing, but data on the effects 
of these other drugs on bone is either missing or has 
yet to be studied. 
Immunosuppressive agents
Glucocorticoids
Glucocorticoids constitute an integral component of 
most post-transplantation regimens, and a brief descrip-
tion of their effects on bone and mineral metabolism 
in the setting of organ transplantation is given here. 
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The immunosuppressive properties of glucocorti-
coids are related to their inhibition of the expression 
of a variety of cytokines, including IL-1, IL-2, IL-6, 
interferon, and tumour necrosis factor (TNF) [3, 4]. 
This inhibition presumably occurs via binding of the 
glucocorticoid–glucocorticoid receptor protein complex 
to a glucocorticoid-responsive element in the regulatory 
region of the target genes. Glucocorticoids also inhibit 
the IGF regulatory system, including IGF-I expression in 
osteoblasts, an effect that probably contributes to their 
inhibitory effect on bone formation. In addition, glu-
cocorticoids inhibit T-cell proliferation [3]. It is of great 
interest that cytokines IL-1, IL-6, TNF, and interferon, 
which are suppressed by glucocorticoids, have been 
found to stimulate bone resorption [3]. These observa-
tions suggest that glucocorticoids, which inhibit these 
cytokines, must cause bone loss and fractures via other 
mechanisms. These mechanisms are thought to include: 
 — inhibition of gastrointestinal calcium absorption and 
stimulation of renal calcium loss, both of which pre-
dispose to negative calcium balance and secondary 
hyperparathyroidism [4];
 — suppression of the hypothalamic–pituitary–gonadal 
axis which decreases gonadal steroidogenesis; 
 — direct suppression of osteoblast recruitment and 
osteoblast function, including inhibition of osteo-
calcin synthesis; 
 — decreased transcription and synthesis of skeletal 
growth factors, such as IGF-I, TGF-, and fibronectin; 
 — enhanced synthesis of collagenase in osteoblasts; 
 — induction of apoptosis of osteoblasts and osteocytes, 
both in vitro and in vivo [4].
Recently, disruption of vascular channels in the bone 
micro-environment, as well as an increased production 
of receptor activator of NFkappa B ligand (RANKL) and 
a decreased synthesis of osteoprotegerin, both stimulat-
ing osteoclast activation, have added to the multifacto-
rial aetiologies of glucocorticoid-induced bone loss [5–8].
Calcineurin inhibitors
Cyclosporine (CsA) and tacrolimus (FK506) are in-
hibitors of calcineurin. They both require binding to 
intracellular proteins: CsA to cyclophilins [9–11] and 
FK506 to FK binding proteins [12, 13]. These proteins are 
called immunophilins and are peptidyl-prolyl cis-trans 
isomerase enzymes [9, 13]. This binding is essential but 
not sufficient for immunosuppression. The complexes, 
in turn, inhibit the intracellular phosphatase enzyme 
calcineurin [9–13], which prevents transcription of 
T lymphocyte cytokine genes and the genes that control 
membrane molecules, such as CD 40 ligand [14, 15]. 
Calcineurin is a serine–threonine phosphatase that is 
uniquely regulated by Ca2+ and calmodulin. Calcineurin 
enzyme interacts with NF-AT (Nuclear Factor of Activat-
ed T cells) [16], which is a family of transcription factors 
necessary for activation of genes, involved in the inflam-
matory and the immune systems. Thus, by inhibiting 
calcineurin [17–22], CsA and FK 506 (see below) prevent 
the activation of NF-AT, with a consequent inhibition of 
growth and differentiation factors critical to the immune 
response. CsA and FK506 have made a huge impact on 
preventing organ rejection and preserving life. One of 
the drawbacks to their use, however, is their propensity 
to cause rapid and profound bone loss [23, 24], a propen-
sity best illustrated in experimental models. This bone 
loss was first observed in the rat model, where adminis-
tration of immunosuppressive doses to normal, young 
or old, male or female oophorectomised rats produced 
a significant loss of trabecular and cortical bone after 
four weeks. The loss was reversible after stopping the 
drug and was dose-dependent [25]. Histomorphometry 
showed this to be an extremely high-turnover bone 
loss with increased markers of resorption and forma-
tion. This action in causing high turnover bone loss is 
dependent on the presence of T lymphocytes.
Tacrolimus (fk506) 
This immunosuppressant, which acts in a similar fa-
shion to CsA, except that it binds to specific FK binding 
proteins, is frequently used as a first-line immunosup-
pressant in place of CsA or to prevent rejection, when 
CsA has failed. It is reputed to have less nephrotoxicity 
than CsA. In vivo effects of FK506 produce the same 
histomorphometric picture of high-turnover bone loss 
as seen with CsA [26].
Clinical studies supporting the role 
of calcineurin inhibitors in bone loss 
after transplantation 
Clinically, there are studies directly implicating the role 
of calcineurin inhibitors in bone loss after organ trans-
plantation [27, 28], which confirms the experimental 
evidence. The first study, linking CsA to bone abnorma-
lity, was published in 1988 [29]. In that study, histology 
in renal transplant patients revealed unexpectedly high 
bone turnover, unlike that seen with glucocorticoid 
administration or in secondary hyperparathyroidism 
[30]. In fact, the turnover resembled that observed in 
experimental studies in the rat. A clinical study in heart 
transplant recipients also attributed the bone loss, seen 
after cardiac transplantation, to CsA, and again, the 
biochemical findings revealed a high-turnover oste-
oporosis [27]. Those studies were all confounded by 
triple immunosuppression, and the role of one drug 
as the culprit cannot be ascertained. Studies with CsA 
monotherapy in transplanted patients, compared to 
other CsA-containing regimens, showed that, after 
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12 months, lumbar BMD did not decrease, and in fact 
increased after 18 months [31–34]. 
The most convincing study was a comparison of CsA 
monotherapy with a non-CsA (prednisone and aza-
thioprine) regimen to isolate the effects of CsA alone in 
renal transplant patients [30]. This study utilised BMD, 
as well as bone histomorphometry as effected targets 
of immunosuppression. The results showed that both 
regimens decreased bone density at the distal radius, 
and less significantly at the lumbar spine, with no dif-
ferences in the degree of bone loss. A histopathological 
analysis showed an increased number of osteoclasts 
and, surprisingly, a decrease in the number of osteob-
lasts and mineral apposition and bone formation rates, 
again with no differences between the groups. The 
findings did not support a role for PTH, either bio-
chemically or histomorphometrically, despite the fact 
that PTH was considered by some investigators to be 
pivotal for bone loss after transplantation. The surpris-
ing decrease in bone formation in that study may be 
related to the time post-transplant, as the subjects were 
140 ± 75 months after transplantation. Similarly, the role 
of tacrolimus (FK506) was also hard to separate from the 
other immunosuppressants used to prevent the rejec-
tion, despite the animal studies, showing either equal 
or more severe loss of bone with FK506 than with CsA, 
with a high turnover remodelling state similar to that 
after CsA [35]. Studies to resolve the role of FK506 were 
done with patients receiving low-dose prednisone and 
FK506, compared to normal-dose glucocorticoids and 
CsA [36]. Those studies showed that, when a cumulative 
dose of steroids was adjusted for both groups, the FK506 
patients after one year did not lose bone, compared to 
the CsA and low-dose prednisone groups. There was no 
relationship to PTH levels. A prospective, longitudinal, 
randomised, double blind study was undertaken to as-
sess the effects of FK 506, glucocorticoids, azathioprine, 
or mycophenalate mofetil (instead of azathioprine) 
and 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) against 
the same immunosuppressive regimen without 
1,25(OH)2D3 (placebo group) [37]. The study duration 
was two years. The objective was to determine whether 
tacrolimus produced bone loss and whether 1,25-di-
hydroxyvitamin D3 could modify or prevent the bone 
loss. The obtained results showed that BMD decreased 
in both groups after transplantation, compared to nor-
mal age-matched subjects. However, BMD increased 
significantly in the lumbar spine in the group receiving 
a vitamin D analogue, although no significant differ-
ences between the groups could be shown. In the femo-
ral neck region, BMD was maintained, but the placebo 
group lost bone significantly. Again, no between-group 
significance could be shown. The conclusion of the 
study could be such that FK506 was associated with 
rapid bone loss, comparable to CsA, which could then 
be modified by the low-dose calcitriol therapy over two 
years. A more convincing study would compare FK506 
against CsA in comparable, post-transplant patients, not 
receiving glucocorticoids to determine whether there 
is any difference between the two CIs in their effect on 
bone mass status. 
The question of the calcineurin inhibitors and bone 
loss is a very complex issue, due to the underlying 
renal osteodystrophy disease, the difference in patient 
profiles, multiple drug administration etc. A direct 
head-to-head comparison of the calcineurin inhibitors 
vs. glucocorticoids alone may never occur, due to patient 
numbers and, perhaps, for ethical reasons. 
Other immune-modifying drugs 
Rapamycin
Rapamycin (sirolimus) is also used to prevent organ 
rejection after transplantation. Rapamycin is a macrolide 
and a product of Streptomyces hygroscopicus. It does not 
inhibit the production of interleukins resulting from 
antigen T-cell activation, but it does inhibit the cellular 
proliferation stimulated by growth factor signal trans-
duction in response to alloantigens [38, 39]. Rapamycin 
binds to the same intracellular protein, immunophilin 
FKBP12, to form a complex, which does not target cal-
cineurin, but rather targets mTor (mammalian target of 
rapamycin). mTor inhibits the translation of mRNAs, 
that encode for cell cycle regulators and T-cell proli-
feration [39]. In vitro studies have shown that, in bone 
marrow stromal cells, rapamycin, like CsA and FK506, 
decreases osteoprotegerin (OPG) mRNA and protein 
levels and increases RANKL, which can potentially 
induce bone loss [40]. Rapamycin may, in addition, act 
via TGF-b to enhance osteoclastogenesis by inducing 
monocyte–macrophage cell differentiation into osteo-
clasts [41]. Conversely, in vivo studies in rats demon-
strate that rapamycin does not cause bone loss but may 
interfere with longitudinal bone growth and, at high 
doses, decrease cortical bone in young rats, which are 
still rapidly growing [38]. An effect on gonadal function 
has also been described with rapamycin [38]. In human 
subjects, studies of rapamycin therapy without gluco-
corticoids and calcineurin inhibitors, investigating bone 
density to ascertain an effect has not been reported, and 
may not be feasible in a transplant population. There 
have been no studies on human populations evaluat-
ing the effect of rapamycin on bone density alone (only 
in combination with glucocorticoids and calcineurin 
inhibitors) so far. Conducting such a study in patients 
after transplantation could be difficult.
 There is a possibility, however, that bone loss with 
calcineurin inhibitors may be mitigated by combining 
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rapamycin with a low-dose CsA, which has been shown 
in rats to prevent bone loss and not compromise im-
mune suppression [42]. Very recently, two open labelled, 
randomised phase 2 studies compared the effects of 
sirolimus (rapamycin) vs. cyclosporine on bone turn-
over markers in 115 patients post-transplantation over 
one year. The patients were all receiving glucocorticoids 
and/or mycophenolate mofetil or azathioprine. Urinary 
excretion of N-telopeptides and serum osteocalcin were 
consistently higher in the patients on CsA, compared 
to sirolimus [43]. Everolimus, which is a derivative of 
rapamycin, has a similar mechanism of action to that 
of rapamycin, but its effect on bone has not yet been 
studied [44].
Mycophenolate mofetil
Mycophenolate mofetil, another additive to the 
immune-modifying drug armamentarium, is now 
becoming the choice to replace azathioprine as part of 
triple therapy, together with CsA or FK506 and gluco-
corticoids, to prevent organ rejection. Mycophenolate 
mofetil is converted in vivo to mycophenolic acid. This 
natural product of penicillium fungi selectively inhib-
its the proliferation of T and B cells, as well as arterial 
wall smooth muscle cells. Most other tissues are resist-
ant to the action of mycophenolate mofetil because of 
an alternate nucleotide synthesis. It also causes less 
bone marrow suppression than azathioprine. Experi-
mentally, in in vivo conditions, there is no evidence for 
bone metabolism alteration, nor for bone volume loss 
[45]. Recently, it has been reported that prednisone and 
mycophenolate mofetil, in the absence of CsA, may also 
be associated with high turnover bone loss on bone 
histomorphometry [46]. This requires further study. 
Azathioprine 
Azathioprine has long been an essential part of therapy 
in combination with CsA and glucocorticoids to prevent 
organ rejection. It is also a purine antagonist and, there-
fore, inhibits rapidly proliferating cells, which include T 
and B lymphocytes and bone marrow haematopoietic 
cells [47]. However, in rats, given azathioprine, albeit for 
a short period, no effect on bone except on bone forma-
tion markers was seen [47]. How this would translate 
with long-term use into clinically relevant outcomes is 
at present unknown.
Summary
The nonsteroidal immunosuppressants belonging to 
the calcineurin inhibiting family, have been shown 
experimentally and clinically to produce severe and 
rapid high-turnover bone loss. In the clinical setting, 
however, these drugs are often used with glucocorti-
coids, which are known to produce severe and rapid 
bone loss. Despite the production of a low turnover 
bone loss by glucocorticoids, the bone biopsy histomor-
phometry in the combination treatment reveals a high 
turnover state. The end result of this combination of 
drugs is rapid and severe bone loss with a very high 
rate of fractures. Other immunosuppressants, such as 
sirolimus, azathioprine, and mycophenolate mofetil, 
have clearly demonstrated adverse effects on the skel-
eton in experimental conditions. The more recent im-
munomodulators have not been well studied in regard 
to bone loss and fracture occurrence in clinical trials. The 
ability to separate the contribution of an individual drug 
as the culprit for producing adverse skeletal effects is 
extremely difficult, given the clinical situation and the 
other confounding variables, found in patients awaiting 
and post-transplantation. The development of immuno-
suppressant drugs that can prevent organ rejection and 
other adverse side effects, including bone loss, would be 
a major advance in the field of organ transplantation. 
Clinical impact of transplantation on bones 
The majority of candidates for organ transplantation 
reveal risk factors that predispose toward osteopenia, 
osteoporosis and subsequent fractures. These factors 
include general debilitation, loss of mobility, poor 
nutrition, cachexia and exposure to certain drugs, in-
cluding glucocorticoids. In addition, many women are 
postmenopausal, and both premenopausal women and 
men with chronic illness may have gonadal dysfunc-
tion. When the disease is present during childhood or 
adolescence, as is the case with cystic fibrosis, there 
may be interference with the attainment of peak bone 
mass. After transplantation, episodes of rejection, usu-
ally reversed by large doses of glucocorticoids and 
cyclosporine, compound the bone loss. Consideration 
of particular issues related to transplantation of specific 
organs follows. 
Kidney transplantation
Patients who undergo renal transplantation have severe 
chronic renal insufficiency or end-stage renal disease 
(ESRD) and most of them have been dialysed for vary-
ing intervals before transplantation. Pre-existing bone 
disease is almost universal in this population. Renal 
osteodystrophy is a general term that encompasses 
all the bone histological alterations that may occur in 
uraemic patients [48]. In a given individual, there may 
be evidence of hyperparathyroidism with or without 
osteitis fibrosa, osteomalacia, low turnover, or a dy-
namic bone disease due to aluminum accumulation 
(or other as yet poorly understood factors), osteoscle-
476
Transplantation osteoporosis Sol Epstein, Michal Stuss
SZ
K
O
LE
N
IE
PO
D
Y
PL
O
M
O
W
E
rosis, particularly of the vertebrae, and macroglobulin 
amyloidosis. Many patients will have ‘mixed’ renal 
osteodystrophy, i.e. a combination of one or more of the 
aforementioned lesions. Other factors that may affect 
the skeletal integrity of patients with ESRD include both 
type 1 and type 2 diabetes, hypogonadism secondary to 
uraemia and diseases such as systemic lupus erythema-
tosus. Several drugs used routinely in the management 
of patients with renal disease, such as loop diuretics 
and aluminum-containing phosphate binders, can also 
affect bone and mineral metabolism. In addition, some 
patients, who are candidates for transplantation, may 
have been previously exposed to glucocorticoids or 
cyclosporine, applied as a therapy for immune complex 
nephritis or other diseases, and thus may already have 
sustained significant bone loss prior to transplantation. 
After renal transplantation, several investigations 
have documented a decline in bone mass [49, 50] and 
increased fracture rate [51, 52]. While the greatest 
insult to the skeleton is related to glucocorticoid and 
cyclosporine exposure, persistent hyperparathyroidism 
probably contributes to the declining bone mass. Re-
cently, a factor relating to the development of second-
ary hyperparathyroidism has been the identification 
of very low levels of 25-hydroxyvitamin D3 (25(OH)
D3) (geometric mean =10.9 ng/mL) in renal transplant 
patients when measured at the end of winter [53]. The 
rate of bone loss is greatest during the first six months 
after transplantation and at sites where cancellous bone 
predominates, such as the lumbar spine [49, 50]. Indeed, 
some reports suggest an increase in bone mass at the 
radius, a site that consists predominantly of cortical 
bone [50]. The rate of lumbar spine bone loss varies 
between 6% and 18% per year, but tends to be some-
what lower than that observed for other transplanted 
organs, such as the liver. This lower rate of bone loss 
is possibly because lower doses of glucocorticoids and 
cyclosporine are used for immunosuppression or newer 
bone sparing immunosuppressants are administered 
after kidney transplantation than after transplantation 
of other solid organs [49, 50]. 
Moreover, rejection is more easily diagnosed, and 
therefore detected earlier, than with other organs, and 
lower doses of immunosuppressive drugs are more 
effective in reversing rejection when it is diagnosed 
earlier. It is accepted that the adverse skeletal effects of 
glucocorticoids and cyclosporine are experimentally 
and clinically dependent upon both dose and duration 
of exposure [25, 54]. Julian et al. reported a decrease 
in lumbar spine BMD of 5.6% at six months, and 7.0% 
at 18 months, after transplantation [49]. Moreover, 
by 18 months, bone density was below the ‘fracture 
threshold’ in ten out of 17 patients. There appears to 
be a gender-determined difference in the site at which 
bone loss occurs [50, 55]. Men have been shown to 
lose more bone at the proximal femur than women in 
the first few months after transplantation. In contrast, 
radial bone density increased in men at six months 
post-transplantation, but not in women. Bone biopsies, 
performed prior to transplantation, revealed changes 
typical for hyperparathyroidism. However, by six 
months after transplantation, the histomorphometric 
picture was more typical for a glucocorticoid effect, 
demonstrating osteoblast dysfunction and decreased 
mineral apposition [55]. Unfortunately, bone biopsies 
were not performed at 18 months when glucocorticoid 
doses were lower. Thus, there was no data either to 
exclude or to incriminate cyclosporine as a factor con-
tributing to bone loss. However, there is some evidence 
in the literature to support a role for cyclosporine in the 
pathogenesis of high turnover state, often apparent in 
renal transplant recipients one year after transplanta-
tion [29]. The increased frequency of cyclosporine use as 
monotherapy in renal transplant patients should clarify 
the relative roles of glucocorticoids and cyclosporine in 
the pathogenesis of post-transplantation bone loss. Re-
cently, 45 renal transplant recipients have been evalu-
ated with quantitative histomorphometry 120 months 
after transplantation. Those treated with cyclosporine 
monotherapy demonstrated significantly lower mineral 
apposition rates than those treated with azathioprine 
and prednisone [30]. 
In general, vertebral fractures are less common 
after kidney transplantation than after transplanta-
tion of other organs. However, appendicular fractures 
are extremely common, particularly in patients after 
transplantation for diabetic nephropathy, in whom the 
incidence of fracture has been reported to be as high 
as 45% [51]. While the reasons for this are not clear 
and are multifactorial (including the accumulation 
of glycosalated end-products), microvascular disease 
and neuropathy (the lack of proprioception and pain 
sensation) may affect fracture incidence by increasing 
the risk of falls. In addition, bone mass may be below 
normal in patients with type 1 diabetes mellitus, even 
before renal transplantation, thus placing such patients 
at higher risk for fracture after transplantation. 
Avascular necrosis occurs commonly after renal 
transplantation [56–61]. The incidence in children is 
6% [56–59] and in adults is 8%. The hip is the most 
commonly affected site. While the association of avas-
cular necrosis with glucocorticoids is well established, 
cyclosporine has also been incriminated in produc-
ing avascular necrosis and bone pain of the hip and 
other weight-bearing bones, such as the knees [62]. 
The known vasospastic or vasoconstrictive properties 
of cyclosporine may contribute to the development of 
avascular necrosis. 
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Cardiac transplantation
Osteoporosis and fractures constitute a major cause of 
morbidity after cardiac transplantation [63–67]. In early 
cross-sectional studies, the prevalence rate of vertebral 
fractures in cardiac transplant recipients ranged be-
tween 18% and 50%, and moderate to severe bone loss 
was present in a substantial proportion of subjects at 
both lumbar spine and the femoral neck [63, 67]. Risk 
factors that may predispose patients with end-stage 
cardiac failure to bone loss even before transplantation 
include exposure to tobacco, alcohol and loop diuret-
ics, physical inactivity, hypogonadism, and anorexia 
which may contribute to dietary calcium deficiency. 
Hepatic congestion and prerenal azotemia may also 
affect mineral metabolism. Although the average bone 
mineral density of patients awaiting cardiac transplan-
tation may not differ significantly from normal, it has 
been observed that approximately 8% to 10% of the 
patients fulfill the World Health Organisation’s criteria 
for osteoporosis and 40% to 50% have osteopenia or 
low bone mass [64, 68]. Prospective longitudinal studies 
have documented rates of bone loss ranging from 2.5% 
to 20%, predominantly during the first year after trans-
plantation [68, 69]. Biochemical changes after cardiac 
transplantation include sustained increases in serum 
creatinine and decreases in 1,25(OH)2D3 concentrations 
[68]. On average, serum testosterone concentrations de-
crease in men, with recovery by the sixth post-transplant 
month [68]. Serum osteocalcin falls precipitously and 
there is a sharp increase in markers of bone resorption 
(hydroxyproline and pyridinium crosslink excretion) 
during the first three months, with return to baseline 
levels by the sixth month [68, 69]. 
This biochemical pattern coincides with the period 
of most rapid bone loss and highest fracture incidence 
and suggests that the early post-transplant period is as-
sociated with uncoupling of formation from resorption. 
It is of interest that at least two studies of subjects treated 
with high doses of glucocorticoids alone, confirmed the 
decrease in serum osteocalcin but demonstrated no 
increase in the markers of bone resorption [70,71]. This 
suggests that the pathogenesis of early bone loss after 
transplantation may be related both to the well-known 
inhibitory effects of glucocorticoids on bone formation, 
and to the effects of cyclosporine A or of another agent 
increasing bone resorption. There is also evidence for 
a high bone turnover state later in the post-transplant 
course, perhaps due to cyclosporine, characterised 
by elevations of both serum osteocalcin and urinary 
excretion of resorption markers [27, 72]. In a recent 
cross-sectional study, Eastell et al. [72] evaluated 50 men, 
ranging from 0.5 to 47 months after cardiac transplanta-
tion. They concluded that bone turnover was increased 
after cardiac transplantation and that the increase was 
due in part to secondary hyperparathyroidism related 
to renal impairment. Thus, biochemical changes later 
in the post-transplant course may be mediated, at least 
in part, by cyclosporine A-induced renal insufficiency. 
The pattern of bone loss after cardiac transplantation 
is similar to that observed after renal [29] or liver trans-
plantation [73–75]. Despite the predilection for gluco-
corticoids to affect the cancellous bone of the vertebrae 
to a greater extent than other sites, Shane et al. [64, 65] 
have reported that there is as much, or even more, bone 
loss at the hip. Moreover, while bone loss at the lumbar 
spine slows or stops after the first six months, femoral 
neck bone loss continues during the second half of 
the first year after transplantation [64, 65]. Moreover, 
these investigators in a recent longitudinal study have 
demonstrated that 36% of patients (54% of the women 
and 29% of the men) suffered from one or more frac-
tures in the first year, despite daily supplementation 
with calcium (1,000 mg) and vitamin D (400 IU) [65]. 
Although the majority of fractures affected the vertebral 
bodies, two patients suffered multiple rib fractures and 
two had fractures of the femoral neck. In women, low 
pretransplant femoral neck bone density predicted the 
risk of vertebral fracture after transplantation. In men, 
however, it was the rate of bone loss after fracture rather 
than the pretransplant bone density that was associated 
with fracture risk. Also of note was the observation 
that patients with normal bone mass also fracture fre-
quently [65]. A European study of 159 cardiac transplant 
recipients reported similar findings [66]. This study 
underscores the need for a complete bone evaluation 
and bone mass measurements prior to, or immediately 
after, transplantation, as well as aggressive intervention 
to prevent bone loss and fractures in all patients, regard-
less of age, sex, or pretransplant bone density. There is 
very little longitudinal data available on the pattern of 
bone loss during the second year after transplantation. 
However, data from Shane et al. suggests that the rate 
of bone loss slows or stops in the majority of patients, 
with some recovery at the lumbar spine noted during 
the third year of observation [65]. Bone loss also slows 
at the hip after the first year; however, in contrast to 
the spine, there has been no significant recovery by the 
fourth post-transplant year [65]. 
Liver transplantation
Patients with liver failure also have risk factors that may 
predispose to fracture after transplantation. In addi-
tion, the doses of immunosuppressive drugs used are 
much larger than those commonly employed after renal 
transplantation. Moreover, since the liver plays a major 
role in cyclosporine metabolism, hepatic dysfunction 
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may also influence its serum concentrations, possibly 
predisposing to cyclosporine toxicity. These factors 
may account for the observation that liver transplant 
recipients have higher rates of bone loss than cardiac 
and renal transplant recipients during the first year 
after transplantation [73, 75, 76]. However, the type of 
liver disease may also be an important risk factor for 
osteoporosis. In one study, 13 out of 20 women with 
primary biliary cirrhosis, a disease characteristically 
associated with low turnover osteoporosis, suffered 
atraumatic fractures of vertebrae, ribs, hips, and long 
bones during the first year after transplantation [76]. 
Patients with alcoholic cirrhosis may also have very 
low bone mass prior to transplantation, perhaps due 
to hypogonadotrophic hypogonadism and excess iron 
deposits in the skeleton. Eastell et al. [76] reported 
that despite the high incidence of fractures in liver 
transplant recipients, bone mass recovered and bone 
histology normalised with increasing survival time after 
transplantation. This, however, has not been a uniform 
finding, and other studies have revealed continued 
losses rather than recovery [75]. Depending upon 
the bone density at the time of transplantation, these 
patients may always be at risk for fractures as survival 
rates and duration increase. As is the case with renal 
and cardiac transplantation, the independent role of 
glucocorticoids and calcineurin phosphatase inhibitors 
in the pathogenesis of bone disease in liver transplant 
patients is difficult to assess since single drug therapy 
is uncommon. The mechanism of bone loss after liver 
transplantation has been studied by bone biopsy in 21 
patients, who underwent tetracycline labelling and 
transiliac crest bone biopsy prior to and three months 
after transplantation. 
Before transplantation, a low turnover state was 
observed, with decreased wall width and erosion 
depth. Postoperative biopsies showed high turnover 
with increased formation rates and activation frequency 
and a trend toward increased indices of resorption [77]. 
In an earlier study, these investigators documented 
a significant increase in PTH concentrations after liver 
transplantation [78]. While increased PTH could account 
for these histomorphometric findings, similar effects are 
observed in animals treated with calcineurin inhibitors 
without a rise in PTH concentrations. 
Lung transplantation
There have been several reports of skeletal compli-
cations in lung transplantation candidates and re-
cipients. As with any chronic illness severe enough 
to require transplantation for survival, patients who 
undergo lung transplantation have predisposing factors 
for low bone mass prior to transplantation. In particu-
lar, tobacco exposure, chronic hypoxemia, immobility, 
glucocorticoid use and certain underlying diseases, 
such as cystic fibrosis, are common in candidates for 
lung transplantation. The prevalence of osteoporosis 
(bone mineral density two standard deviations below 
aged-matched controls) varies between 55% and 66% 
at the spine and up to 78% for the hip [79, 80]. The 
prevalence of vertebral fracture in candidates before 
transplantation is also high, varying between 25% and 
29% [79, 80]. Adults with cystic fibrosis are probably at 
even greater risk for bone disease than other patients 
who undergo lung transplantation. A recent study of 
70 adults with cystic fibrosis observed virtually all to 
have either osteoporosis or low bone mass. Reported 
fracture rates were double those in the general popula-
tion, while rib and vertebral fractures were 10-fold and 
100-fold greater, respectively. The strongest predictors 
of BMD were body mass index, cumulative prednisone 
dose and pubertal age [81].
The incidence of new fractures after lung trans-
plantation is also very high [82], even in patients who 
receive antiresorptive therapy. It has recently been 
reported that 11 (10 women) of 30 lung transplant re-
cipients (37%), all of whom had received daily calcium 
(1,000 mg) and vitamin D (800 IU) and antiresorptive 
therapy (injectable calcitonin, cyclic etidronate, pa-
midronate, or alendronate) sustained a total of 54 new 
fractures during the first year after transplantation [82]. 
The average time to first fracture was 4.5 months. The 
commonest fracture sites were ribs, vertebrae, pelvis, 
and sacrum [82, 83]. In addition, the fracture incidence 
may be underestimated, as patients with existing rib 
or vertebral fractures may not be candidates for lung 
transplantation because of the effect on lung function 
post operatively. Moreover, despite antiresorptive 
therapy, 50% had a significant decrease in BMD. Bio-
chemical markers of bone turnover were significantly 
higher in those who lost bone and in those who frac-
tured. Paediatric lung transplantation is becoming 
more frequent and both osteoporosis and reduced 
growth velocity can be expected in these children 
[84]. Similar to other transplanted organs, a high bone 
turnover state with elevated osteocalcin concentrations 
has been reported after lung transplantation [85].
Bone marrow transplantation 
Bone marrow transplantation is performed with in-
creasing frequency and for expanding indications. Low 
BMD has also been reported in patients after bone 
marrow transplantation [86], probably related to 
both pre- and post-transplant factors. In preparation 
for transplantation, patients receive myeloablative 
therapy (alkylating agents and/or total body irradia-
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tion) and commonly develop profound and frequently 
permanent hypogonadism, which almost certainly 
contributes to bone loss. Two studies have documented 
low BMD in hypogonadal women after bone mar-
row transplantation [87] and shown that hormone 
replacement therapy is associated with significant 
increases in BMD [88]. A study of nine adults, un-
dergoing high-dose glucocorticoid and CSA therapy 
for graft-versus-host disease (GVHD), observed sig-
nificant bone loss in most patients [89]. Other factors 
include low vitamin D levels, physical inactivity and 
the malignancy itself [90]. A more recent study has 
documented that low bone mass antedates bone mar-
row transplantation, particularly in subjects with prior 
glucocorticoid exposure, and that post-transplant bone 
loss is particularly severe in patients who undergo 
allogeneic bone marrow transplantation, probably 
because of their increased propensity for GVHD [91]. 
In these patients, the rate of bone loss was 11.7% at 
the femoral neck and 3.9% at the spine [91]. In the first 
prospective study in children and adolescents, there 
was a 15% increase in osteopenia and a 3% increase 
in osteoporosis in the first year post-transplant. The 
reduction in lumbar spine BMD at six months corre-
lated with the cumulative dose of glucocorticoids [90]. 
Biochemical data suggests that bone loss after marrow 
transplantation is a high turnover state with increases 
in resorption markers and alkaline phosphatase acti-
vity [91–93], although some studies show an initial 
decrease, followed by a recovery towards baseline at 
six months [90]. In adult patients, non traumatic frac-
tures occurred in 10.6% of patients three years after 
marrow transplantation [94].
Evaluation of candidates for transplantation 
Abundant data is now available documenting the 
high prevalence of bone disease in candidates for all 
types of transplantation. Therefore, a complete skeletal 
evaluation is indicated. This evaluation should occur 
prior to transplantation, so that potentially treatable 
abnormalities of bone and mineral metabolism may 
be addressed and the skeletal condition of the patient 
optimised before transplantation. This evaluation 
should include a full history with particular emphasis 
upon risk factors for osteoporosis such as family history, 
prevalent low-energetic fractures, medical conditions 
(thyrotoxicosis, diabetes mellitus, renal disease, rheu-
matoid, and intestinal or liver disorders), poor lifestyle 
choices (physical inactivity, dietary calcium and vitamin 
D deficiency, excessive caffeine and alcohol intake, to-
bacco use), and exposure to drugs (diphenylhydantoin, 
antiepileptics, lithium, loop diuretics, glucocorticoids, 
prolonged and large doses of heparin, excessive doses 
of thyroid hormone etc.). Additional risk factors im-
portant in women include premature menopause, 
postmenopausal status, a history of anorexia nervosa 
or prolonged episodes of amenorrhea. In men, it is 
important to exclude hypogonadism. A physical exa-
mination should focus upon diseases that predispose 
to osteoporosis, such as hypogonadism, thyrotoxicosis 
and Cushing’s syndrome. Risk factors for falling (sight, 
hearing, balance, and muscle strength) should also be 
assessed. Bone density of the spine and hip and plain 
radiographs of the thoracic and lumbar spine are the 
most important tests to obtain prior to transplantation. 
The biochemical evaluation should include a chem-
istry panel, thyroid function tests, intact PTH and 
vitamin D metabolites, and total and free testosterone, 
follicle-stimulating hormone (FSH), and luteinising 
hormone (LH) concentrations in men. Markers of bone 
formation (serum osteocalcin and bone-specific alkaline 
phosphatase) and resorption (urinary deoxypyridino-
line or serum/urinary C and N-telopeptide) can also 
provide valuable information. 
Summary of the evaluation of candidates 
for organ transplantation
 — history and physical examination, with attention to 
risk factors for osteoporosis;
 — bone densitometry by dual-energy X-ray absorptio-
metry (DXA);
 — thoracic and lumbar spine radiographs or vertebral 
fracture assessment (VFA) by DXA technique;
 — serum calcium, parathyroid hormone, 25-hydroxy-
vitamin D, thyroid function tests and bone turnover 
markers;
 — in men, serum total and/or free testosterone, FSH, 
and LH;
 — urine for calcium and markers of bone resorption 
(optional).
In the interest of cost control, it could be argued 
that the battery of biochemical tests may be unneces-
sary if the bone density measurement is normal and 
calcium and vitamin D supplementation are planned. 
However, if the pre-transplant bone density is low, 
the biochemical evaluation can alert the physician to 
the aetiology of low bone mass and guide appropri-
ate therapy. 
After transplantation, serum and urine indices of 
mineral metabolism are less crucial. Measurement of 
bone density remains important and should be per-
formed at 6–12 monthly intervals for the first two years 
and annually thereafter. Bone biopsy may be necessary 
after renal transplantation, since many experts remain 
reluctant to use bisphosphonates in patients with 
adynamic bone disease, despite the lack of any data 
either supporting or excluding the use of these drugs 
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in this setting. Although transiliac crest bone biopsy 
remains a research tool, more histomorphometric stu-
dies would be very helpful in confirming the theories of 
the pathogenesis of transplantation osteoporosis. With 
the advent of non invasive techniques to measure bone 
quality reflecting microarchitectural changes and bone 
strength, new information on the pathogenesis and risk 
of fracture, as well as monitoring the benefits of therapy, 
may become more logical.
Management of transplantation 
osteoporosis
The general principles for the treatment of transplan-
tation osteoporosis are similar to those for any type 
of osteoporosis. Therapy may be initiated during 
the waiting period before transplantation or in the 
initial 6- 12 months after transplantation. In addition, 
no long-term transplant recipient with established 
osteoporosis and/or fractures should be neglected. 
It must be emphasised that prevention of bone loss 
accompanying transplantation in a transplant recipi-
ent is probably more effective in reducing morbidity 
than the treatment of already established osteoporo-
sis. During the waiting period before transplanta-
tion, rehabilitation therapy should be prescribed, as 
tolerated, to maximise the patient’s condition and 
physical fitness. In general, calcium supplementation 
should be prescribed at doses of 1,000–1,500 mg per 
day, depending upon age, gender, menopausal status, 
and dietary intake. Either calcium citrate or calcium 
carbonate is acceptable; however, the carbonate form 
should be taken with food to enhance absorption and 
it can cause constipation. All patients should receive 
the Recommended Daily Allowance of vitamin D (800 
IU daily). However, given the frequency of vitamin D 
insufficiency in these patients, the amount needs to 
be increased if measurement of 25-hydroxy-vitamin 
D is low. Hormone replacement therapy should be 
considered in all postmenopausal women, as well as 
in premenopausal amenorrheic women, where there 
are no contraindications to such therapy. Hypogonadal 
men should also be offered testosterone replacement. 
Generally accepted guidelines for gonadal hormone 
replacement should apply to these patients. 
After transplantation, pharmacologic strategies 
should be instituted immediately to prevent bone loss 
and fractures. It must be emphasised that very few 
controlled prospective studies have been reported that 
support the use of specific therapies. The recommenda-
tions described in this chapter are based upon such data 
as currently exists, together with experience, acquired 
in similar clinical situations, and with supportive ex-
perimental evidence. 
Summary of recommendations for the management 
of organ transplant recipients
 — encourage transplant physicians to use the lowest 
possible dose of glucocorticoids and to consider 
alternative therapies for rejection (e.g. OKT3, ra-
pamycin and mycophenolate mofotil);
 — obtain bone mineral density routinely in patients 
accepted for transplantation and refer for evalua-
tion/therapy all patients with low bone mass (T score 
between –1.0 and –2.5) or osteoporosis (T score –2.5);
 — ensure calcium intake of 1,000-1,500 mg daily, both 
before and after transplantation;
 — ensure vitamin D intake of 800–1,000 IU, or as 
needed to maintain serum 25-OHD concentrations 
above 30 ng/mL;
 — encourage participation in a physical rehabilitation 
programme, both before and after transplantation; 
 — replace gonadal steroids in hypogonadal women 
and men;
 — begin antiresorptive therapy, preferably a bisphos-
phonate, before transplantation in patients with 
antecedent osteoporosis/fractures or low bone mass; 
 — begin antiresorptive therapy, preferably a bisphos-
phonate, immediately or as soon as possible after 
transplantation in patients with normal or low bone 
mass and continue for at least the first post-trans-
plant year;
 — measure BMD at 6-12 monthly intervals for the first 
two years after transplantation.
Potential therapies for transplantation 
osteoporosis 
Potential therapies for transplantation osteoporosis 
include:
 — vitamin D and analogues;
 — oestrogen;
 — testosterone;
 — calcitonin;
 — bisphosphonates;
 — newer drugs such as Denosumab.
Vitamin D and analogues 
Administration of vitamin D or its analogues is usually 
recommended after transplantation. Sambrook et al. 
[95] found calcitriol to be efficacious in patients with 
glucocorticoid-induced osteoporosis. Although the 
role of vitamin D and its analogues in transplanta-
tion osteoporosis remains unclear, these investigators 
recently reported, in an abstract form, that calcitriol 
(0.5–0.75 mcg/day) prevented spine and hip bone loss 
during the first six months after heart or lung trans-
plantation and was as effective as cyclic etidronate [96]. 
Hypercalcemia and hypercalciuria are the major side 
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effects of the therapy with the active analogue and 
may develop either suddenly or at any time during 
the course of treatment. Thus, frequent urinary and 
serum monitoring may be required. If hypercalcemia 
occurs, it must be recognised and reversed promptly 
because of the adverse effects on renal function and the 
life-threatening potential of a severely elevated serum 
calcium concentration. Supplemental calcium and any 
vitamin D preparations must be discontinued until 
calcium and 25(OH)D3 values normalise. Although 
one may be tempted to permanently discontinue 
pharmacologic doses of vitamin D or its metabolites in 
view of the necessary serial monitoring and potential 
dangers, it seems reasonable to recommence therapy 
at a lower dose. The exact mechanism by which vi-
tamin D and its analogues may influence post-trans-
plantation bone loss is uncertain. They may overcome 
glucocorticoid-induced decreases in intestinal calcium 
absorption, reduce the potential for secondary hyper-
parathyroidism, promote differentiation of osteoblast 
precursors into mature cells, or influence the immune 
system and potentiate the immunosuppressive action 
of cyclosporine [97, 98]. 
In summary, given the requirement for serial 
monitoring and the narrow therapeutic window with 
regard to hypercalcemia and hypercalciuria, we regard 
pharmacologic doses of vitamin D and its analogues as 
adjunctive rather than primary therapy for the preven-
tion and treatment of transplantation osteoporosis. 
Oestrogen 
In postmenopausal women, or premenopausal women 
with amenorrhea or irregular menses, oestrogen re-
placement should be recommended, provided that 
there are no contraindications. The dose is the same as 
that used for prevention or therapy of postmenopausal 
osteoporosis and may be given either orally or transder-
mally. In women with an intact uterus, progesterone 
must be prescribed in addition to prevent endometrial 
cancer. Continuous rather than cyclic therapy is pre-
ferred after transplantation, as oestrogen enhances 
hepatic metabolism of cyclosporine (and presumably 
FK506) and may theoretically compromise immuno-
suppression, although it is not known if such an effect 
occurs in these patients. For patients who cannot take 
oestrogen, tamoxifen [99] or newer selective oestrogen 
receptor modulators (SERMs) such as raloxifene [100], 
may well be a suitable alternative. Although no trials 
of these drugs in organ transplant recipients have 
been published, raloxifene has been shown to reduce 
cyclosporine-induced bone loss in the rat model [101]. 
Hyperlipidaemia, produced by glucocorticoids, cy-
closporine, and its analogues, may also be ameliorated 
by oestrogen, tamoxifen, and raloxifene, although no 
systematic studies have been conducted that address 
this particular issue. 
Few trials have evaluated the efficacy of oestrogen in 
preventing bone loss and fractures after transplantation. 
Therefore, the recommendation to prescribe oestrogen 
for this purpose is based in part upon the observation 
that 17-estradiol prevents cyclosporine-induced bone 
loss in the oophorectomised rat [102]. In addition, 
a wealth of clinical data supports the protective effect 
of oestrogen on the skeleton and one cross-sectional 
study suggests that oestrogen and progesterone therapy 
are associated with higher bone density in women on 
glucocorticoids [103]. The exact mechanism by which 
oestrogen protects the skeleton is unknown. However, 
oestrogen is associated with the inhibition of bone re-
sorbing cytokines, such as IL-1, IL-6, and IL-11. Recent 
work implicates IL-1 [104] as a potential candidate in 
the pathogenesis of high turnover bone loss in the 
cyclosporine-treated rat, making it conceivable that 
oestrogen may modify bone loss in this model by inhib-
iting this cytokine. However, potential side effects on 
cardiovascular and breast cancer have to be recognised.
In bone marrow transplantation, in which hypogo-
nadism is a predominant feature, 12 months of hormone 
replacement therapy (HRT) was associated with sig-
nificantly increased bone density in a small number of 
women, without adversely affecting liver enzymes [88]. 
There may also be an advantage to combine HRT with 
a bisphosphonate, particularly in the light of a recent 
study in which an addition of alendronate in a group of 
postmenopausal women on stable doses of HRT caused 
a significant increase in BMD, but no fracture data for 
combined therapy is available.
Testosterone 
Men with serious chronic illnesses, such as hepatic, 
renal or cardiac failure, are commonly hypogonadal. 
In addition, high doses of both glucocorticoids [103] 
and cyclosporine (greater than 15 mg/kg body weight) 
suppress the hypothalamic–pituitary–gonadal axis 
and produce hypogonadism [105, 106]. Testosterone 
deficiency, both before and after transplantation, may 
contribute to the risk of bone loss and fractures [67, 69, 
95]. However, given the complexity of the clinical situ-
ation after transplantation, it is not possible to ascertain 
whether testosterone deficiency is an independent risk 
factor for fracture or bone loss. In any event, since an-
drogen deficiency is known to cause low bone mass in 
men, it is not unreasonable to prescribe testosterone in 
men who are truly hypogonadal. Testosterone therapy 
is not without risks. Of special concern is the potential 
for induction or exacerbation of hyperlipidaemia in 
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patients already prone to accelerated atherosclerosis 
from hypertension, diabetes, glucocorticoid, and cy-
closporine drug therapy [107]. In addition, prostatic 
hypertrophy and liver abnormalities are side effects of 
androgen therapy. 
However, after successful transplantation, serum 
testosterone levels frequently normalise, so that an-
drogen therapy may only be required as a temporary 
measure [67, 69, 95]. Thus, it can be argued that tempo-
rary administration of testosterone after transplantation 
constitutes physiologic hormone replacement rather 
than pharmacological therapy. The risks of prostatic 
hyperplasia and liver abnormalities can be minimised 
by administering testosterone transdermally, rather 
than by injection. If testosterone therapy is recom-
mended, patients must be cautioned about potential 
risks and benefits. Monitoring should include monthly 
measurement of serum lipids and hepatic enzymes and 
regular prostate examinations. Whether testosterone 
replacement with calcium supplements and vitamin 
D is sufficient to prevent transplantation osteoporosis 
is not known. However, it would be more prudent to 
include additional antiresorptive therapy to protect 
the skeleton. 
Calcitonin
In the therapy of osteoporosis, calcitonin has been 
shown to increase bone density and reduce vertebral 
fractures in patients with osteoporosis, although it is 
not as effective as other current therapies. Despite 
many years of experience, the optimum dose, the route 
of administration and efficacy of continuous versus 
intermittent dosing remain unclear. Both injectable 
and inhaled calcitonin has been used successfully to 
treat glucocorticoid-induced bone loss in humans [108]. 
While its use in transplant recipients has not been 
established by controlled trials, an experimental work 
in a rat model has demonstrated that cyclosporine-in-
duced bone loss can be prevented by calcitonin [109]. 
However, literature reports are rather far from being 
consistent regarding the use of calcitonin to prevent 
bone loss and fractures after transplantation. The usual 
practice is to prescribe synthetic salmon calcitonin, 100 
units daily by subcutaneous injection, or intranasal 
calcitonin (100–200 IU), as soon as immunosuppressive 
therapy is begun. This intranasal dose varies accord-
ing to the transplanted organ [110, 111]. Valero et al. 
administered either injectable calcitonin or etidronate 
to liver transplant recipients and found that lumbar 
spine bone density increased by 6–8% with no dif-
ference in the efficacy between the drugs [112]. By 
contrast, other investigators have not found calcitonin 
to be particularly effective [111, 113].
Bisphosphonates 
Bisphosphonates, which act by inhibiting osteoclastic 
bone resorption, have been used successfully to prevent 
and treat glucocorticoid-induced bone loss. Published 
studies include first-, second-, and third-generation 
bisphosphonates, such as etidronate, pamidronate, 
tiludronate, alendronate, risendronate, ibandronate 
and, most recently, zolendronate [114–123]. Because 
transplantation osteoporosis can be considered as one 
form of glucocorticoid-induced osteoporosis, and as cy-
closporine- and tacrolimus-induced bone loss are char-
acterised experimentally by simultaneously increased 
bone formation and bone resorption, bisphosphonates 
may prove to be highly successful in the prevention of 
transplantation osteoporosis. Some [121–123], although 
not all [124], studies suggest that bisphosphonates can 
prevent bone loss and fractures after transplantation. 
A single intravenous dose of pamidronate (60 mg), given 
during the first two weeks after transplantation and fol-
lowed by cyclical editronate for the remainder of the first 
year, prevented lumbar spine and femoral neck bone 
loss and significantly reduced the fracture incidence, 
compared to patients who received only calcium and 
400 IU of vitamin D [122]. A similar experience has been 
reported with intravenous pamidronate in kidney [121] 
and, even more dramatically, in liver [123] transplant 
recipients, where fractures were prevented in the group 
treated with pamidronate. Alendronate has been used 
in the prevention of osteoporosis after cardiac, liver, 
and renal transplantation and the Shane group’s own 
clinical experience suggests that this drug is effective in 
this setting [125]. At present, these drugs constitute the 
most promising approach to the prevention of this often 
crippling form of osteoporosis. As with other forms of 
therapy, many issues remain to be resolved, such as 
whether continuous or intermittent (cyclical) therapy 
should be used and at what level of renal impairment 
these drugs should be avoided. However, a very re-
cent study, intravenously administering a long-acting 
potent N-containing bisphosphonate, zoledronic acid, 
in a prospective, double blind, placebo controlled trial 
to 62 post-liver transplant patients at seven days, and 
then at months 1, 3, 6, and 9 has shown that, after ad-
justing for weight and PTH levels, BMD increased at 
the lumbar spine, femoral neck and total hip by 1.1%, 
2.7%, and 2.4%, respectively after one year [120]. Before 
the administration of N-containing bisphosphonates, 
the patient should be made aware of the very rare but 
important side effects, such as osteonecrosis of the 
jaw, subtrochanteric fractures and joint and muscle 
pains besides the upper GIT disturbances, which can 
be overcome with intravenous preparations. However, 
as no direct cause and effect for these side effects has 
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been proven, they should not preclude physicians from 
prescribing these drugs as the first line of therapy.
Other therapeutic options 
At the present time, the use of the lowest possible doses 
of glucocorticoid and calcineurin phosphatase inhibi-
tors offers the best option. The regimens which do not 
use either glucocorticoids or calcineurin inhibitors may 
prove the most advantageous to the skeleton. A hu-
man monoclonal antibody to RANKL (denosumab) 
has recently been approved to treat osteoporosis [126] 
and trials are underway to examine its effect in gluco-
corticoid induced bone disease. This may have a place 
in post-transplant disease, as it potently inhibits bone 
resorption and can be given twice per annum as a s.c. 
injection. This drug  inhibits the osteoclast cell cycle but 
has little or minimal side effects on renal function and 
may exacerbate hypocalcemia seems promising but no 
data exists in transplant patients. Currently, the most 
exciting areas of investigation involve the agents that 
stimulate bone formation (growth hormone, growth 
hormone releasing peptide, PTH or its analogues, the 
IGF family, including the IGF binding proteins, pros-
taglandins, particularly of the E series [127, 128], and 
the TGF-superfamily, including bone morphogenic 
protein). PTH (1-34) and other agonists of PTH1 receptor 
may enhance cell differentiation into the osteoblastic 
line and reduce their adipogensis [129, 130], but further 
studies are necessary to prove this hypothesis. Antibod-
ies, which inhibit the action of sclerostin, a major factor 
in the WNT-beta catenin pathway promoting bone 
resorption, are also undergoing clinical trials and this 
may have impressive anabolic effects. Such drugs are of 
theoretical value, particularly in the setting of glucocor-
ticoid therapy, where the inhibition of bone formation 
is a major contributor to bone loss. Newer analogues of 
vitamin D, that promote calcium absorption and stimu-
late bone formation without hypercalcemia [131], may 
also be valuable additions to the therapeutic armamen-
tarium. Prospective, controlled clinical trials are sorely 
needed, not only to evaluate the existing regimens, 
but also to study these newer therapies. This may be 
unrealistic, given the trial design, the required number 
of patients, different immunosuppressive regimens, 
comorbid conditions etc.
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